StocksMedium•4 November 2026•
1 min read
Arcutis Biotherapeutics Raises 2026 Guidance as ZORYVE Sales Surge 45%
Key Facts
1Arcutis reported $143.9 million in ZORYVE net product revenue for the third quarter of 2026.
2The company revised its full-year 2026 sales guidance upward.
Arcutis Biotherapeutics reported $143.9 million in ZORYVE net product revenue for the third quarter ended September 30, 2026. Benzinga reported that the company revised its full-year 2026 sales guidance upward following these strong results. Product revenues increased 45% compared to the same period in 2025, with ZORYVE topical foam contributing $75.1 million to the total revenue figure.
Net income for the quarter reached $8.8 million, or $0.07 per share, up from $7.4 million in the third quarter of 2025. ARQT closed at $32 on November 3, 2026, having traded between a low of $31.27 and a high of $32.39 during that session. The company held $259.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.